ASHISHPRADHAN,MDRandolph,NJ•609.610.4469•pradhana123@gmail.com•www.linkedin.com/in/ashishpradhanmd

PUBLICATIONSPapers1. BergvallN,MakinC,LahozR,AgashivalaN,PradhanA,CapkunG,etal.(2014)RelapseRatesinPatientswith

Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims DatabaseStudy.PLoSONE9(2):e88472.doi:10.1371/journal.pone.0088472

2. Niklas Bergvall, Allison A. Petrilla, Swapna U. Karkare, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan,GoranaCapkun,CharlesMakin,CatherineBalderstonMcGuiness&JonathanR.Korn(2014)Persistencewithandadherencetofingolimodcomparedwithotherdisease-modifyingtherapiesforthetreatmentofmultiplesclerosis:aretrospectiveUSclaimsdatabaseanalysis,JournalofMedicalEconomics,17:10,696-707

3. Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, AllisonPetrilla, Swapna U. Karkare, Catherine Balderston McGuiness & Jonathan R. Korn (2013) Comparativeeffectivenessof fingolimodversus interferonsorglatirameracetate for relapserates inmultiple sclerosis:aretrospectiveUSclaimsdatabaseanalysis,CurrentMedicalResearchandOpinion,29:12,1647-1656

4. Hamet P, Campbell N, Curnew G, Eastwood C, Pradhan A. AVAPROMISE: A randomized clinical trial forincreasingadherencethroughbehaviouralmodification inessentialhypertension.ExperimentalandClinicalCardiology.2003,7(4):165-172.

5. PradhanA, LevineM.Warfarinuse inatrial fibrillation:A randomsample surveyof familyphysicianbeliefsandpreferences.CanJClinPharmacol.2002Winter;9(4):199-202.

6. P. Baures, A. Pradhan, W. Ojala, W. Gleason, R. Mishra, R. Johnson. Synthesis and Dopamine ReceptorModulatingActivityofUnsubstitutedandSubstitutedTriprolineAnaloguesof L-Propyl-L-Leucyl-Glycinamide(PLG).Bioorganic&MedicinalChemistryLetters.1999,Vol-9:2349-2352.

7. E.Khalil,A.Pradhan,S.Venkatraman,W.Ojala,W.Gleason,R.Mishra&R.Johnson.SynthesisandDopamineReceptor Modulating Activity of Substituted Bicyclic Thiazolidine Lactam Peptidomimetics of L-Propyl-L-Leucyl-Glycinamide.JournalofMed.Chemistry.1999,42(15):2977-2987.

8. M. Evans, A. Pradhan, S. Venkatraman, W. Ojala, W. Gleason, R. Mishra & R. Johnson. Synthesis andDopamineReceptorModulatingActivityofNovelPeptidomimeticsofL-Prolyl-L-Leucyl-GlycinamideFeaturingdisubstitutedAminoAcids.JournalofMed.Chemistry.1999,42(8):1441-1447.

9. E.Khalil,W.Ojala,A.Pradhan,V.Nair,W.Gleason,R.Mishra&R. Johnson.Design,Synthesis&DopamineReceptorModulatingActivityof SpiroBicyclic Peptidomimeticsof L-Propyl-L-LeucylGlycinamide. JournalofMed.Chemistry.1999,42(22):628-637.

10. P.Baures,W.Ojala,W.Costain,M.Ott,A.Pradhan,W.Gleason,R.Mishra&R.Johnson.Design,Synthesis&Dopamine Receptor Modulating Activity of Diketopiperazine Peptidomimetics of L-Propyl-L-LeucylGlycinamide.JournalofMed.Chemistry.1997,40(22):3594-3600.

Abstracts1. JeffreyCohen,AshishPradhan,RebeccaGottschalk,YuChen,LudwigKappos,OngoingSafetyand

Effectiveness:Aninterimanalysisofongoingfingolimodtreatment.AAN20162. Long-termSafetyofFingolimod:AnInterimAnalysisoftheLONGTERMSCohort(S4.006).JeffreyCohen,Philipp

VonRosenstiel,RebeccaGottschalk,AshishPradhan,YingZhangandLudwigKappos.AcceptedasPlatformpresentationatAAN2015

ASHISHPRADHAN,MD|PUBLICATIONS,PAGE2

Randolph,NJ•609.610.4469•pradhana123@gmail.com•www.linkedin.com/in/ashishpradhanmd

3. P.S.Giacomini,H.Butzkueven,S.Cohan,T.Olsson,D.Rothenbacher,B.Weller,T.Ziemssen,A.Gupta,A.Pradhan,M.Cremer,T.Blankenbiller,A.Sinha,D.Tomic,P.vonRosenstiel,andM.Trojano.Baselinecharacteristicsandinterimanalysisresultsoffingolimodcohortintheworld-widePost-ApprovalSafetyprogram(PASSAGE).AAN2014

4. NiklasBergvall,RaquelLahoz,NeetuAgashivala,AshishPradhan,GoranaCapkun-Niggli,JonathanRKorn,AllisonAPetrilla,SwapnaUKarkare,CatherineBalderstonMcGuiness,CharlesMakin.Relapseratesamongpatientswithmultiplesclerosiswhoswitchfrominterferontherapytofingolimodorglatirameracetate:aretrospectiveUSclaimsdatabaseanalysis.AAN2014

5. Niklas Bergvall, Raquel Lahoz, Neetu Agashivala,Ashish Pradhan, Gorana Capkun-Niggli, Jonathan R Korn,AllisonAPetrilla,SwapnaUKarkare,CatherineBalderstonMcGuiness,CharlesMakin.Relapseratesamongpatientswithahistoryofrelapsestreatedwithfingolimodcomparedwithinterferonsorglatirameracetateforthetreatmentofmultiplesclerosis:aretrospectiveUSclaimsdatabaseanalysis.AAN,2014

6. NiklasBergvall,RaquelLahoz,NeetuAgashivala,AshishPradhan,GoranaCapkun-Niggli,JonathanRKorn,AllisonAPetrilla,SwapnaUKarkare,CatherineBalderstonMcGuiness,CharlesMakinPersistenceandadherenceoffingolimodcomparedwithotherdisease-modifyingtherapiesforthetreatmentofmultiplesclerosis:aretrospectiveUSclaimsdatabaseanalysis.AAN2014

7. MalikS,LopezV,ChenR,WuW,PradhanA,FranklinS,WongN.TreatmentofCardiovascularRiskFactorsforUSpersonswithDiabetes.Diabetes.2005,Vol54,Suppl1,A581,2409.

8. PradhanA,RayS,CisloP.ImpactoftheNationalServiceFramework(NSF)forcoronaryarterydisease(CAD)onphysiciancomplianceofprescribingaspirinandstatinsforsecondarypreventionintheUnitedKingdom(UK).ValueinHealth,May2004,Volume7,Issue3:334-335.

9. GroverS,BrewerC,CoupalL,ZowallH,PradhanA.Estimating thebenefitsofantihypertensive therapy:anassessmentofpulsepressure.ValueinHealth.May-June2002,5(3):PMI6,211.

10. A.Pradhan,M.Levine.Warfarinuseinatrialfibrillation:arandomsamplesurveyoffamilyphysicianbeliefs.ClinicalPharmacologyandTherapeutics.2000,67(2):PIII-45,153.

11. A.Pradhanetal.QualityofLifeamongstNewandChronicUsersofAcidSuppressionTherapy:CanadianJofClinInvestMed.1999;SupplNo22(4):S6.(Abstract)